Friday, April 03, 2026

Parmita Mishra’s Major Insights: Nature’s Hidden Depths, Medical Biases, and the Cellular Revolution in Drug Discovery


Parmita Mishra’s Major Insights: Nature’s Hidden Depths, Medical Biases, and the Cellular Revolution in Drug Discovery
Parmita Mishra (
@parmita
), founder and CEO of Precigenetic, describes herself as a scuba diver, engineer, and biologist “interested in things that lie deep.” With a background that spans biology and engineering, she uses her X platform (35k+ followers) to share a distinctive blend of awe at nature’s ingenuity, sharp critiques of pharmaceutical pipelines, and bold visions for next-generation biotech. Her recent tweets—spanning viral threads, scientific curiosities, and company updates—reveal consistent themes: life’s extraordinary resilience, the narrow cages of human perception and traditional medicine, and the urgent need for cell-level, data-rich tools to fix drug discovery. Nature’s Ingenuity Outpaces Human ExpectationsMishra repeatedly highlights obscure biological phenomena that challenge our assumptions about resilience, evolution, and possibility. Snails can regenerate entire eyes, with genes that appear conserved across vertebrates—raising the theoretical prospect of one day activating similar pathways to cure blindness in humans. Malaria parasites contain iron crystals that spin nonstop, powered by hydrogen peroxide decomposition—the same chemistry used to launch rockets.
She also points to the speed of post-extinction recovery: after the asteroid impact that killed the dinosaurs 66 million years ago, new plankton species emerged in under 2,000 years (far faster than the previously estimated 30,000). Her takeaway is humbling: “Life doesn’t give a fuck about extinction event… Mother Nature just needs like 2000 years to move on.” Humans are not the resilient apex; we are merely one transient part of a far larger, faster-evolving biosphere.
These examples underscore a core insight: nature operates on scales and with mechanisms we barely glimpse. Mishra’s company, Precigenetic, refuses to accept the limits of current tools—repeatedly calling for “a spectrometer for EVERYTHING,” even speculating that ghostly phenomena might one day register as calibration noise rather than the supernatural. The Cage of Human PerceptionHuman senses and tools are inherently limited. The “visible spectrum” is named for what we can see, yet scientists recently identified a new color, “olo,” positioned between blue and green at a saturation level impossible for unaided eyes (requiring a specialized laser setup). “The visible spectrum is a cage,” she writes. “You live in it.”
This theme of hidden realities extends to her broader call for deeper instrumentation. Whether it’s cellular responses invisible to behavioral observation or wavelengths beyond human vision, Mishra argues we must expand our observational toolkit to match nature’s complexity.Exposing Biases in Drug Discovery: The ADHD Thread as Case StudyOne of Mishra’s most detailed and personal threads dismantles myths around stimulant medications for ADHD. Discovered accidentally in the 1930s when they calmed hyperactive boys, these drugs were never “designed” for the full spectrum of ADHD. Clinical trials, diagnostic criteria (DSM), and dosing were built around one narrow phenotype: young, hyperactive, mostly white males. Hyperactivity—the symptom that disrupts classrooms and adults around the child—received the most attention, while inattentiveness, disorganization, and initiation problems (which devastate adult lives) were poorly addressed.
Gender bias compounds the issue. Girls, who more often present with inattentive ADHD, were (and still are) underdiagnosed; boys received interventions roughly 10 years earlier on average. Women were systematically excluded from early-phase trials until 1993, and even today represent only 29–34% of participants in many industry-sponsored studies. Stimulants help many (Mishra herself credits them with changing her life), but they primarily tame hyperactivity that often fades naturally with age. The deeper cellular and cognitive mechanisms remain unsolved.
Her broader point: phenotypic screens (watching behavior) and traditional pipelines bake in societal biases before any drug reaches patients. The solution isn’t abandoning medication—it’s moving discovery to the cellular level where drugs actually act.Precigenetic’s Bet: “Cell Cinema” as the Great EqualizerMishra’s company is positioned as the missing piece. She argues that even commoditized AI drug design will fail without rich, unbiased data. Precigenetic is building “Cell Cinema”—real-time, label-free video of living human cells responding to drugs, combined with chemically resolved observation and what she calls MBOP hardware.
Key advantages:
  • Unbiased starting point: Cells derived from any sex, age, or genetic background can be tested before clinical trials or DSM criteria ever enter the picture.
  • Continuous observation: Not static snapshots but “film” of dynamic responses, revealing polypharmacology and true mechanisms.
  • Practical beachhead: The company starts with the organ every oral small-molecule drug hits first—the liver—aiming to create the world’s best liver-toxicity screen, saving billions and lives.
  • Expansion path: From liver to brain, blood-brain barrier, kidneys, gut, and skin—modeling in analog what digital alone cannot capture.
In short, “the next generation of drugs won’t be discovered by accident.” They’ll come from eyes on cells, AI, and infrastructure that sidesteps recruitment biases and phenotypic blind spots. She frames this as “quite literally the last crucial job left to start by mankind.”
Mishra ties this directly to AI hype: Google or others may commoditize design, but without cellular-level data like hers, most diseases remain unsolved. Philosophical Undercurrents: Delusion, Persistence, and the Long GameBeyond science, Mishra offers pragmatic wisdom for founders and humans. Surviving the world “without destroying your mental health requires absolute delusion” (optimistic delusion, she clarifies). In startups, “your conscious is sometimes playing checkers. Your subconscious is playing chess.” Persistence matters. She also urges posting “bangers and threads” on topics like male pattern hair loss, showing her belief in public scientific discourse as a force multiplier.Why It MattersParmita Mishra’s body of insights forms a coherent worldview: nature is deeper, faster, and more ingenious than we credit; our current tools (sensory, clinical, and technological) are narrower than we admit; and the path forward lies in unbiased, cell-first observation. Through Precigenetic’s Cell Cinema platform, she is not merely critiquing the status quo—she is building the instrumentation to transcend it, starting with liver toxicity and scaling toward precision medicines that actually heal rather than manage symptoms.
Her posts blend wonder, frustration, and optimism in equal measure. Whether marveling at a parasite’s rocket engine or calling out decades of gender bias in psychiatry, Mishra consistently returns to the same imperative: look deeper, measure better, and build medicines worthy of the biology we’re trying to fix. In an era of AI hype and incremental pharma pipelines, her message is refreshingly grounded in cells, data, and the living systems that refuse to be caged.

at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)